Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

IMW 2019 | Limitations of genome sequencing in cancer treatment

Francesco Maura • 14 Sep 2019
IMW 2019
Multiple Myeloma

Francesco Maura, MD, Memorial Sloan Kettering Cancer Center, New York, NY, outlines the limitations of genome sequencing in cancer treatment and suggests integration between different fields to overcome these hurdles, speaking at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Francesco Maura

Is high-risk smoldering myeloma a misnomer - do these patients already have myeloma?
2:02
Is high-risk smoldering myeloma a misnomer - do these patients already have myeloma?
Francesco Maura • 8 Dec 2025
Replacing standard FISH panels with WGS in multiple myeloma
1:49
Replacing standard FISH panels with WGS in multiple myeloma
Francesco Maura • 8 Dec 2025
Defining high-risk myeloma in the era of immune therapies: progress made, unmet needs & more
13:45
Defining high-risk myeloma in the era of immune therapies: progress made, unmet needs & more
Francesco Maura • 24 Oct 2025
Two types of resistance to BCMA-directed treatments in multiple myeloma: how do they differ?
1:49
Two types of resistance to BCMA-directed treatments in multiple myeloma: how do they differ?
Francesco Maura • 19 Sep 2025

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Francesco Maura • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Francesco Maura • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Francesco Maura • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Francesco Maura • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals